{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:30Z","timestamp":1793296110388,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40265-018-0864-z","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T06:31:05Z","timestamp":1517207465000},"page":"245-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Ledipasvir\/Sofosbuvir: A Review in Chronic Hepatitis C"],"prefix":"10.1007","volume":"78","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.jhep.2016.07.005","volume":"65","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Birerdinc A, Henry L. Hepatitis C infection: a multi-faceted systemic disease with clinical, patient-reported and economic consequences. J Hepatol. 2016;65:S109\u201319.","journal-title":"J Hepatol."},{"key":"864_CR2","doi-asserted-by":"crossref","unstructured":"Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl S1):47\u20137.","DOI":"10.1111\/liv.13027"},{"key":"864_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40265-015-0401-2","volume":"75","author":"A Majumdar","year":"2015","unstructured":"Majumdar A, Kitson MT, Roberts SK. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. Drugs. 2015;75:823\u201334.","journal-title":"Drugs."},{"key":"864_CR4","unstructured":"European Medicines Agency. Harvoni 90 mg\/400 mg film-coated tablets: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu. Accessed 2 Nov 2017."},{"issue":"11","key":"864_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40262-016-0397-0","volume":"55","author":"P German","year":"2016","unstructured":"German P, Mathias A, Brainard D, et al. Clinical pharmacokinetics and pharmacodynamics of ledipasvir\/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet. 2016;55(11):1337\u201351.","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"864_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-015-0381-2","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Ledipasvir\/sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75(6):675\u201385.","journal-title":"Drugs."},{"issue":"3","key":"864_CR7","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.02524-15","volume":"60","author":"G Cheng","year":"2016","unstructured":"Cheng G, Tian Y, Doehle B, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother. 2016;60(3):1847\u201353.","journal-title":"Antimicrob Agents Chemother."},{"issue":"20","key":"864_CR8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889\u201398.","journal-title":"N Engl J Med."},{"issue":"16","key":"864_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483\u201393.","journal-title":"N Engl J Med."},{"issue":"20","key":"864_CR10","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879\u201388.","journal-title":"N Engl J Med."},{"issue":"10","key":"864_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/jvh.12549","volume":"23","author":"M Mizokami","year":"2016","unstructured":"Mizokami M, Dvory-Sobol H, Izumi N, et al. Resistance analyses of Japanese hepatitis co-infected patients receiving sofosbuvir or ledipasvir\/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016;23(10):780\u20138.","journal-title":"J Viral Hepat."},{"issue":"4","key":"864_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","volume":"66","author":"D Wyles","year":"2017","unstructured":"Wyles D, Dvory-Sobol H, Svarovskaia ES, et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir. J Hepatol. 2017;66(4):703\u201310.","journal-title":"J Hepatol."},{"key":"864_CR13","doi-asserted-by":"crossref","unstructured":"Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501-12.e1.","DOI":"10.1053\/j.gastro.2016.06.002"},{"key":"864_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910\u20138.","journal-title":"J Hepatol."},{"issue":"11","key":"864_CR15","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/jmv.24885","volume":"89","author":"H Kan","year":"2017","unstructured":"Kan H, Imamura M, Kawakami Y, et al. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. J Med Virol. 2017;89(11):1963\u201372.","journal-title":"J Med Virol."},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677\u201390.","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"864_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with or without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"864_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofv056","volume":"2","author":"KV Kowdley","year":"2015","unstructured":"Kowdley KV, An D, Pang PS, et al. Analysis of subgroup differences in the ION-3 trial of ledipasvir-sofosbuvir in chronic hepatitis C infection. Open Forum Infect Dis. 2015;2(2):1\u20132.","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"864_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hep.28334","volume":"63","author":"JM Wilder","year":"2016","unstructured":"Wilder JM, Jeffers LJ, Ravendhran N, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology. 2016;63(2):437\u201344.","journal-title":"Hepatology"},{"issue":"4","key":"864_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/hep.28425","volume":"63","author":"S Saab","year":"2016","unstructured":"Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir\/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63(4):1112\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"864_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.27826","volume":"62","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62(1):79\u201386.","journal-title":"Hepatology"},{"issue":"6","key":"864_CR22","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/hep.27724","volume":"61","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatol. 2015;61(6):1798\u2013808.","journal-title":"Hepatol."},{"issue":"6","key":"864_CR23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/hep.27814","volume":"61","author":"D Wyles","year":"2015","unstructured":"Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61(6):1793\u20137.","journal-title":"Hepatology"},{"key":"864_CR24","unstructured":"Lawitz E, Pockros P, Yang JC, et al. Ledipasvir\/sofosbuvir regimens for the retreatment of patients who failed sofosbuvir-based regimens [abstract no. O-011]. Hepatol Int. 2016;10(Suppl 1):S9."},{"key":"864_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13616","author":"E Tam","year":"2017","unstructured":"Tam E, Luetkeymer AF, Mantry PS, et al. Ledipasvir\/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: findings from two randomized trials. Liver Int. 2017. https:\/\/doi.org\/10.1111\/liv.13616.","journal-title":"Liver Int."},{"issue":"7","key":"864_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/jmv.24767","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol. 2017;89(7):1248\u201354.","journal-title":"J Med Virol."},{"issue":"4","key":"864_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/hep.29005","volume":"65","author":"KV Kowdley","year":"2017","unstructured":"Kowdley KV, Sundaram V, Jeon CY, et al. Eight weeks of ledipasvir\/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology. 2017;65(4):1094\u2013103.","journal-title":"Hepatology"},{"issue":"9","key":"864_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/liv.13103","volume":"36","author":"AA Butt","year":"2016","unstructured":"Butt AA, Yan P, Shaikh OS, et al. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int. 2016;36(9):1275\u201383.","journal-title":"Liver Int."},{"key":"864_CR29","doi-asserted-by":"crossref","unstructured":"Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-40.e5.","DOI":"10.1053\/j.gastro.2016.08.004"},{"issue":"1","key":"864_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jvh.12611","volume":"24","author":"EB Tapper","year":"2017","unstructured":"Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017;24(1):22\u20137.","journal-title":"J Viral Hepat."},{"issue":"6","key":"864_CR31","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.28782","volume":"64","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893\u20139.","journal-title":"Hepatology"},{"key":"864_CR32","doi-asserted-by":"crossref","unstructured":"Curry MP, Tapper EB, Bacon B, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017:1\u20139.","DOI":"10.1111\/apt.14204"},{"issue":"2","key":"864_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hep.28625","volume":"64","author":"LI Backus","year":"2016","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405\u201314.","journal-title":"Hepatology"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/apt.13696","volume":"44","author":"LI Backus","year":"2016","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of ledipasvir\/sofosbuvir \u00b1 ribavirin vs. ombitasvir\/paritaprevir\/ritonavir + dasabuvir \u00b1 ribavirin in 6961 genotype 1 patients treated in routine clinical practice. Aliment Pharmacol Ther. 2016;44:400\u201310.","journal-title":"Aliment Pharmacol Ther."},{"key":"864_CR35","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3117","author":"LI Backus","year":"2017","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther. 2017. https:\/\/doi.org\/10.3851\/IMP3117.","journal-title":"Antivir Ther."},{"issue":"2","key":"864_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep.28995","volume":"66","author":"WF Balistreri","year":"2017","unstructured":"Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371\u20138.","journal-title":"Hepatology"},{"issue":"1","key":"864_CR37","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/MPG.0000000000001754","volume":"66","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Stepanova M, Balistreri W, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Ped Gastroenterol Nutr. 2018;66(1):1112\u20136.","journal-title":"J Ped Gastroenterol Nutr."},{"issue":"6","key":"864_CR38","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1053\/j.gastro.2017.01.017","volume":"152","author":"EJ Gane","year":"2017","unstructured":"Gane EJ, Hyland RH, Yang Y, et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology. 2017;152(6):1366\u201371.","journal-title":"Gastroenterology."},{"issue":"1","key":"864_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/cid\/cix289","volume":"65","author":"JJ Feld","year":"2017","unstructured":"Feld JJ, Ramji A, Shafran SD, et al. Ledipasvir-sofosbuvir plus ribavirin in treatment-naive patients with hepatitis C virus genotype 3 infection: an open-label study. Clin Infect Dis. 2017;65(1):13\u20139.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"864_CR40","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","volume":"149","author":"EJ Gane","year":"2015","unstructured":"Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454\u201361.","journal-title":"Gastroenterology."},{"issue":"4","key":"864_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/hep.28706","volume":"64","author":"A Abergel","year":"2016","unstructured":"Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64(4):1049\u201356.","journal-title":"Hepatology"},{"issue":"9","key":"864_CR42","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","volume":"15","author":"A Kohli","year":"2015","unstructured":"Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049\u201354.","journal-title":"Lancet Infect Dis."},{"issue":"4","key":"864_CR43","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1473-3099(15)00529-0","volume":"16","author":"A Abergel","year":"2016","unstructured":"Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459\u201364.","journal-title":"Lancet Infect Dis."},{"issue":"12","key":"864_CR44","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/ajg.2017.399","volume":"112","author":"MH Nguyen","year":"2017","unstructured":"Nguyen MH, Trinh H, Do S, et al. Open label study of 8 vs. 12 weeks of ledipasvir\/sofosbuvir in genotype 6 treatment naive or experienced patients. Am J Gastroenterol. 2017;112(12):1824\u201331.","journal-title":"Am J Gastroenterol."},{"key":"864_CR45","unstructured":"Asahina Y, Itoh Y, Ueno Y, et al. Ledipasvir\/sofosbuvir in the treatment of Japanese patients with chronic HCV genotype 2 infection [abstract no. 1184]. Hepatology. 2017;66(1 Suppl):638A."},{"key":"864_CR46","unstructured":"Pol S, ANRS\/AFEF HEPATHER study group. Safety and efficacy of the combination sofosbuvir-ledipasvir in HCV mono-infected patients from the French Cohort ANRS CO22 HEPATHER [abstract no. 1087]. Hepatology. 2017;66(1 Suppl):582A."},{"issue":"5","key":"864_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/apt.13925","volume":"45","author":"M Cornberg","year":"2017","unstructured":"Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017;45(5):688\u2013700.","journal-title":"Aliment Pharmacol Ther."},{"key":"864_CR48","doi-asserted-by":"crossref","unstructured":"Tsertsvadze T, Chkhartishvilli N, Abutidze A, et al. Real-world effectiveness of sofosbuvir and ledipasvir\/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia [abstract no.1167]. Hepatology. 2017;66(1 Suppl):627-8A.","DOI":"10.1016\/S0168-8278(17)31977-3"},{"issue":"6","key":"864_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"M Manns","year":"2016","unstructured":"Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685\u201397.","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"864_CR50","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649\u201359.","journal-title":"Gastroenterology."},{"issue":"8","key":"864_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705\u201313.","journal-title":"N Engl J Med."},{"key":"864_CR52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/cid\/ciw349","volume":"63","author":"CL Cooper","year":"2016","unstructured":"Cooper CL, Naggie S, Saag MS, et al. Successful retreatment of HCV\/HIV-coinfected patients who failed 12 weeks of LDV\/SOF. Clin Infect Dis. 2016;63:528\u201331.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"864_CR53","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jvh.12554","volume":"23","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016;23(11):857\u201365.","journal-title":"J Viral Hepat."},{"issue":"4","key":"864_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourliere","year":"2015","unstructured":"Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397\u2013404.","journal-title":"Lancet Infect Dis."},{"issue":"Suppl 1","key":"864_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000451010","volume":"92","author":"S Hagiwara","year":"2017","unstructured":"Hagiwara S, Nishida N, Watanabe T, et al. Outcome of combination therapy with sofosbuvir and ledipasvir for chronic type C liver disease. Oncology. 2017;92(Suppl 1):3\u20139.","journal-title":"Oncology."},{"key":"864_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12765","author":"M Barone","year":"2017","unstructured":"Barone M, Iannone A, Shahini E, et al. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ital-c network. J Viral Hepatitis. 2017. https:\/\/doi.org\/10.1111\/jvh.12765.","journal-title":"J Viral Hepatitis."},{"issue":"4","key":"864_CR57","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/jgh.13620","volume":"32","author":"VL Ferreira","year":"2017","unstructured":"Ferreira VL, Assis Jarek NA, Tonin FS, et al. Ledipasvir\/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: a pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32(4):749\u201355.","journal-title":"J Gastroenterol Hepatol."},{"issue":"1","key":"864_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/liv.12886","volume":"36","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Pol S, et al. The impact of ledipasvir\/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016;36(1):42\u20138.","journal-title":"Liver Int."},{"key":"864_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001907","author":"F Abbalkhail","year":"2017","unstructured":"Abbalkhail F, Elsiesy H, Elbeshbeshy H, et al. Treatment of patients with hepatitis C virus infection (genotype 4) with ledipasvir-sofosbuvir in the liver transplant setting. Transplant Proc. 2017. https:\/\/doi.org\/10.1097\/TP.0000000000001907.","journal-title":"Transplant Proc."},{"issue":"11","key":"864_CR60","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/lt.24614","volume":"22","author":"RM Kwok","year":"2016","unstructured":"Kwok RM, Ahn J, Schiano TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl. 2016;22(11):1536\u201343.","journal-title":"Liver Transpl."},{"issue":"4","key":"864_CR61","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.29258","volume":"66","author":"V Saxena","year":"2017","unstructured":"Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology. 2017;66(4):1090\u2013101.","journal-title":"Hepatology"},{"issue":"2","key":"864_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7326\/M16-1205","volume":"166","author":"M Colombo","year":"2017","unstructured":"Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166(2):109\u201317.","journal-title":"Ann Intern Med."},{"issue":"2","key":"864_CR63","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/hae.12791","volume":"22","author":"CAM Stedman","year":"2016","unstructured":"Stedman CAM, Hyland RH, Ding X, et al. Once daily ledipasvir\/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214\u20137.","journal-title":"Haemophilia."},{"issue":"2","key":"864_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/hae.13178","volume":"23","author":"CE Walsh","year":"2017","unstructured":"Walsh CE, Workowski K, Terrault NA, et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017;23(2):198\u2013206.","journal-title":"Haemophilia."},{"issue":"4","key":"864_CR65","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/apt.14197","volume":"46","author":"A Mangia","year":"2017","unstructured":"Mangia A, Sarli R, Gamberini R, et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 2017;46(4):424\u201331.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"864_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/hep.27890","volume":"62","author":"SA Alqahtani","year":"2015","unstructured":"Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62(1):25\u201330.","journal-title":"Hepatology"},{"key":"864_CR67","unstructured":"Gilead Sciences. HARVONI\u00ae (ledipasvir and sofosbuvir): US prescribing information. 2017. http:\/\/www.gilead.com. Accessed 1 Nov 2017"},{"key":"864_CR68","doi-asserted-by":"crossref","unstructured":"Rosenblatt R, Kumar S, Mehta A, et al. Baseline creatinine clearance is a predictor of worsening renal function while on treatment with sofosbuvir-ledipasvir [abstract no. Su1464]. Gastroenterology. 2016;150(4 Suppl. 1):S1107.","DOI":"10.1016\/S0016-5085(16)33741-6"},{"key":"864_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.390","author":"P German","year":"2017","unstructured":"German P, Mathias A, Brainard D, et al. A thorough QT study to evaluate the effects of supratherapeutic doses of ledipasvir on the QTc interval in healthy subjects. Clin Pharmacol Drug Dev. 2017. https:\/\/doi.org\/10.1002\/cpdd.390.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"864_CR70","unstructured":"WHO. Global hepatitis report 2017. 2017. http:\/\/www.who.int\/hepatitis\/. Accessed 30 Nov 2017."},{"issue":"1","key":"864_CR71","first-page":"153","volume":"61","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016;61(1):153\u201394.","journal-title":"J Hepatol."},{"key":"864_CR72","unstructured":"European Medicines Agency. Vosevi (sofosbuvir, velpatasvir and voxilaprevir) 400 mg\/100 mg\/10 mg film coated tablets: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu. Accessed 4 Nov 2017."},{"issue":"3","key":"864_CR73","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jcph.830","volume":"57","author":"W Carter","year":"2017","unstructured":"Carter W, Connelly S, Struble K. Reinventing HCV treatment: past and future perspectives. J Clin Pharmacol. 2017;57(3):287\u201396.","journal-title":"J Clin Pharmacol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-0864-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0864-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0864-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:49:10Z","timestamp":1659098950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-0864-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0864-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"assertion":[{"value":"29 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lesley Scott is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.Additional information about this Adis Drug Review can be found at\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}